Business Context and Reporting Period
Cartesian Therapeutics, Inc. filed its Form 10-K for the fiscal year ended December 31, 2023. The company is a clinical-stage biotechnology company developing mRNA cell therapies for autoimmune diseases. The November 2023 merger with Old Cartesian transformed the company from its legacy Selecta business into an mRNA cell-therapy-focused company; the company began trading under the ticker RNAC on November 14, 2023.
The lead candidate is Descartes-08, an autologous anti-BCMA mRNA CAR-T therapy. The company is also developing Descartes-15 and the preclinical allogeneic mRNA MSC candidate Descartes-33.
Financial Performance and Position
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Collaboration and license revenue | $26.0 million | $110.8 million | Down 77% |
| Research and development expense | $71.8 million | $72.4 million | Down 1% |
| General and administrative expense | $40.6 million | $23.9 million | Up 70% |
| Operating loss | $86.4 million | Operating income of $14.5 million | Material deterioration |
| Net loss | $219.7 million | Net income of $35.4 million | Decrease of $255.1 million |
| Net loss per share | $1.66 | Net income per share of $0.24 | Unfavorable change |
| Cash flow from operations | $(51.2) million | $(31.6) million | Higher cash use |
| Cash, cash equivalents and restricted cash | $78.3 million | $108.0 million | Down $29.8 million |
There were no product sales. Revenue was primarily generated from collaboration and licensing arrangements, including Sobi, Astellas, Takeda and Sarepta-related activities. The filing does not provide a clearly defined product gross margin or operating margin; the company remains loss-making and development-stage.
At December 31, 2023, total assets were $305.1 million, including $150.6 million of acquired in-process research and development and $48.2 million of goodwill. Total liabilities were $444.7 million, and stockholders’ deficit was $440.2 million. The company had no outstanding borrowings after repaying its term loan in September 2023; the payoff totaled $22.3 million.
Management stated that cash, cash equivalents and restricted cash at year-end, together with $40.0 million of net proceeds from the November 2023 private placement received after year-end, were expected to fund planned operations and capital expenditures into mid-2026. The financial statements state more conservatively that these resources would fund current planned operations for at least the next twelve months.
Material Changes Versus the Prior Comparable Period
- Revenue declined by $84.8 million, primarily because of lower revenue under the Sobi license as clinical-supply shipments and reimbursed Phase 3 costs declined.
- General and administrative expense increased by $16.7 million because of higher stock-based compensation, personnel costs and merger-related professional fees.
- Net results were adversely affected by $149.6 million of expense from remeasurement of Series A Preferred Stock forward contract liabilities and $18.3 million of expense from remeasurement of the contingent value right liability.
- The company recorded a $19.0 million income tax benefit related to legacy Selecta tax attributes and merger accounting.
- Operating cash use increased by $19.6 million, while financing activities used $13.1 million, primarily reflecting debt repayment and settlement of merger-related equity awards, partially offset by $20.3 million of gross Series A Preferred Stock proceeds received in 2023.
- The company implemented a restructuring that paused or deprioritized several legacy programs and reduced headcount by approximately 79% by year-end. Restructuring expense was $6.4 million, with $3.9 million remaining accrued at December 31, 2023.
Clinical Progress, Outlook and Key Risks
- In an open-label Phase 1b/2a MG study, all seven patients receiving six once-weekly high-dose infusions showed marked and durable clinical improvement at month nine; five of seven maintained clinically meaningful improvement at month 12. These results were from a small, open-label study and require confirmation.
- The randomized, placebo-controlled Phase 2b MG trial was enrolling, with at least 30 expected completers and topline results expected in mid-2024.
- The company expected to initiate a Phase 2 SLE trial in the first half of 2024 and a Phase 1 Descartes-15 trial in relapsed/refractory multiple myeloma in the first half of 2024.
- Descartes-08 had FDA Orphan Drug Designation for MG. No product candidate had received marketing approval, and the company expects continuing losses and additional financing needs.
- Key risks include clinical failure or delays, patient enrollment, manufacturing and patient-specific logistics, regulatory scrutiny of CAR-T therapies, uncertain reimbursement, competition, intellectual property challenges and dependence on third parties.
- The CVR liability was $358.6 million at December 31, 2023. It is intended to be settled from specified legacy-asset proceeds, including Sobi-related milestones and royalties, rather than from general company cash; however, actual proceeds are uncertain.
- Series A Preferred Stock holders may obtain redemption rights beginning 18 months after the merger closing, subject to conversion-related limitations. A significant cash redemption could reduce funds available for operations and require additional financing.
- Two stockholder lawsuits were filed in February 2024 concerning disclosures related to the proposed conversion of Series A Preferred Stock. Management considers the claims without merit and intends to defend them.
- Management and the auditor identified a material weakness in internal control over financial reporting involving documentation and review controls for the valuation of acquired in-process research and development and the CVR obligation. The auditor issued an adverse opinion on internal control effectiveness, while issuing an unqualified opinion on the financial statements.
Most Important Facts for Investors to Verify
- Read the audited financial statements and notes for the valuation assumptions underlying the $150.6 million in-process research and development asset, $358.6 million CVR liability and $28.3 million forward contract liability.
- Confirm the status and results of the Phase 2b Descartes-08 MG trial and the planned SLE and Descartes-15 trials.
- Reconcile the stated cash runway with actual post-year-end financing, operating cash burn, clinical spending and potential Series A Preferred Stock redemptions.
- Assess the dilution and governance implications of the 435,120.513 Series A Preferred Stock shares outstanding, the 99,140.326 shares subject to delayed issuance as of year-end, and the conversion terms.
- Monitor remediation of the material weakness and any future restatements, control deficiencies or changes in valuation assumptions.
- Review the CVR agreement, Sobi license economics and the probability and timing of future milestone, royalty or asset-monetization proceeds.